StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
CELCBullishCorporate Developmentsnews
High materiality8/10

Celcuity Reports Strong Progress in Gedatolisib Trials Ahead of FDA Review

May 14, 2026, 4:17 PM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The positive trial results for gedatolisib enhance its commercial viability and could catalyze stock price appreciation leading up to FDA approval. Historical examples show that successful trial results often lead to stock surges.

AI summary

What happened, with direct paths to the underlying reporting

Celcuity Inc. reported significant progress in the gedatolisib clinical trials, particularly the VIKTORIA-1 study, which showed improved progression-free survival. With plans for a supplemental New Drug Application in Q3 2026, potential FDA approval appears promising, which could drive performance and investor interest in CELC.

  • CELC's gedatolisib shows significant improvement in progression-free survival in trials.
  • Phase 3 VIKTORIA-1 results bolster gedatolisib's potential for FDA approval by Q3 2026.
  • VIKTORIA-2 trial expanded for endocrine-sensitive female patients with advanced breast cancer.
  • New subcutaneous formulation of gedatolisib under development; first patent filed.
  • Q1 2026 net loss increased to $52.8 million, impacting stock performance.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event